"Secret" compulsory license hearings in India for Roche's Tarceva under TRIPs rule
A hearing by the Indian Patent Office to approve a compulsory license application under a rarely-used provision of the World Trade Organization's agreement on Trade-Related Intellectual Property Rights (TRIPs) has been delayed from the end of February, in order to allow Swiss drug major Roche the opportunity to plead for the right to attend the full hearing. At stake is the patent in India for the cancer drug Tarceva (erlotinib). The Indian firm lobbying for the opportunity to manufacture a generic version of the lung cancer therapy is Hyderabad-based Natco Pharma, for export to neighboring Nepal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze